Hengkang Pharma provide 90% and 95% or customer purity for all below oligonucleotide, All oliconucleotide only for research and development.
Hengkang Pharma provide siRNA, ASO, etc custom synthesis service.
Name
Bepirovirsen
Synonym
GSK-3228836; IONIS-HBVRx; GSK836
Description
Beprovir is an antisense oligonucleotide developed by Ionis Pharmaceuticals Inc. It is a viral protein inhibitor. Currently, the highest development stage of the drug is Phase III clinical trial for the treatment of chronic hepatitis B.
Packing Size
100mg/ 1g /10g
Name
Fomivirsen
Synonym
ISIS-2922; Vitravene; Fomivirsenum; 福米韦生
Description
Fomivirsen sodium is an antisense oligonucleotide and a protein biosynthesis inhibitor. Currently, the highest development stage of this drug is withdrawal from the market, and it is used to treat cytomegalovirus retinitis.
Packing Size
100mg/ 1g /10g
Name
Mipomersen sodium
Synonym
ISIS-301012; Kynamro; 米泊美生
Description
Mipomersen sodium is a first-in-class small molecule drug developed by Ionis Pharmaceuticals Inc. It is an APOB inhibitor. Currently, the highest development stage of this drug is withdrawal from the market, and it is used to treat type II hyperlipoproteinemia.
Miravirsen is an antisense oligonucleotide developed by Roche, which is a hepatitis C virus replication inhibitor and MIRN122 microRNA inhibitor. Currently, the highest development stage of this drug is no progress and it is used to treat chronic hepatitis C and hepatitis C.
Packing Size
100mg/ 1g /10g
Name
Olpasiran
Synonym
ARO-LPA; AMG-890; ARC-LPA; RNAi ARC-LPA
Description
Olpasiran is a siRNA developed by Arrowhead Pharmaceuticals Inc and Amgen, and is an Lp(a) inhibitor. Currently, the highest development stage of the drug is Phase III clinical trial, which is used to treat atherosclerosis and atherosclerotic plaques.
Remlarsen is a microRNA developed by The University Of Texas Southwestern Medical Center and is a collagen inhibitor. Currently, the highest stage of development of this drug is clinical phase II for the treatment of keloids.
Packing Size
100mg/ 1g /10g
Name
Tivanisiran
Synonym
SYL-1001; SYL-1001-DP
Description
Tivanisiran is a siRNA developed by Sylentis Sa, a TRPV1 antagonist. Currently, the highest development stage of the drug is clinical phase III, which is used to treat Sjogren-Larsson syndrome and dry eye syndrome.
Tofusen is a first-in-class antisense oligonucleotide developed by Ionis Pharmaceuticals Inc and the Ludwig Institute for Cancer Research. It is a SOD inhibitor. Currently, the highest development stage of this drug is approval for marketing for the treatment of amyotrophic lateral sclerosis.
Inksilan sodium is a first-in-class siRNA developed by Alnylam Pharmaceuticals Inc. It is a PCSK9 inhibitor. Currently, the highest development stage of this drug is approval for marketing, which is used to treat hypercholesterolemia, dyslipidemia, carotid artery disease, heterozygous familial hypercholesterolemia and atherosclerosis. On December 9, 2020, Inxlan sodium was approved by the European Medicines Agency (EMA) and is marketed by Novartis Europharm Ltd under the trade name Leqvio®. (EMEA/H/C/005333)
Packing Size
100mg/ 1g /10g
Name
Synonym
Description
Packing Size
100mg/ 1g /10g
More information, please feel free to contact us, business department email bd1@hengkangpharm.cn
